THU0476 Efficacy of Denosumab for The Treatment of Osteoporosis in Japanese Patients with Rheumatoid Arthritis

Background Recent studies have reported that RA patient with osteoporosis administered Denosumab (DMAB) was associated with significant increases of low bone mineral density (BMD) at lumbar spine and femoral neck. DMAB increases cortical bone more effective than any other drug for treatment of osteoporosis. Objectives Therefore, we investigated efficacy of DMAB in the patient with RA for 12 months at lumbar spine, femoral neck, and radius. Methods Sixty RA patients with osteoporosis were administered DMAB between April 2014 and October 2015, 45 patients were evaluated for 12 months in our institute. The following items were examined just before administered and at the time of 6 months and 12 months after administration: BMD of lumbar/femur/radius, Biomarker (total P1NP, TRACP-5b), radiograph of the hand. Also, comparisons were performed on the basis of efficacy of DMAB at the time of 12 months in radius between the patients with the poorly effected group (NR group), and the patients with the well-effected group (R group). Results After treatment of DMAB at 12 months, 5.2 percent increase of BMD at the lumbar spine was obtained, 4.2 percent increase at the femoral neck. However, there was not significant change at the distal third of the radius. Comparing the NR group to the R group, there was statistically significant difference in Larsen grade at the wrist. Conclusions DMAB significantly increases bone mineral density in the patient with RA. However, in the patient with severe joint destruction, DMAB could not increase BMD at the radius. Disclosure of Interest None declared